Genprex (NASDAQ:GNPX) Stock Falls 1.1% – Time to Sell?

Genprex (NASDAQ:GNPX)’s share price fell 1.1% during mid-day trading on Monday. The stock traded as low as $2.57 and last traded at $2.69. 275,523 shares traded hands during mid-day trading, an increase of 1% from the average session volume of 272,023 shares. The stock had previously closed at $2.72.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Genprex Stock Down 1.1%

The business has a 50 day moving average of $3.58 and a 200 day moving average of $12.84. The company has a market capitalization of $2.21 million, a P/E ratio of -0.02 and a beta of -0.99.

Genprex (NASDAQ:GNPX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($9.40) earnings per share for the quarter.

Institutional Investors Weigh In On Genprex

An institutional investor recently bought a new position in Genprex stock. Mayflower Financial Advisors LLC acquired a new stake in shares of Genprex (NASDAQ:GNPX) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 20,000 shares of the company’s stock, valued at approximately $36,000. Mayflower Financial Advisors LLC owned approximately 0.22% of Genprex at the end of the most recent reporting period. 14.05% of the stock is currently owned by institutional investors.

About Genprex

Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s lead product candidate is ofranergene obadenovec, also known as REQORSA Therapeutics, an investigational nonviral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells.

Genprex has primarily studied REQORSA in combination with other treatments for non-small cell lung cancer, including immune checkpoint inhibitors and targeted therapies.